Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
09926 AKESO
RTNominal unchange46.650 0.000 (0.000%)
Others

04/01/2022 16:02

Akeso (09926) drug gets phase III clinical trial approval

[ET Net News Agency, 4 January 2022] Akeso, Inc. (09926) said Cadonilimab (PD-1/ CTLA-4
bi-specific antibody, research and development code: AK104), the world's first-in-class
novel immuno-oncology drug independently developed by the company, combined with
concurrent chemoradiotherapy obtained approval from the Center for Drug Evaluation (CDE)
of the National Medical Products Administration of the People's Republic of China to
initiate a phase III clinical trial for the treatment of locally advanced cervical cancer.
This is the first phase III clinical trial for locally advanced cervical cancer
immunotherapy in China. (RC)

Remark: Real time quote last updated: 28/03/2024 18:00
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.